Kristy Belcher
Nurse Practitioner · Inverness, FLNPI 1831697812
Payments from drug & device makers
Across 77 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$177
- Medtronic$106
- Otsuka America Pharmaceutical, Inc.$105
- Bayer$103
- Abbott$102
- Amgen$101
- plus $811 from 24 others
What the payments were for
- Food & beverage$1,504100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $177 |
| Medtronic | 4 | $106 |
| Otsuka America Pharmaceutical, Inc. | 6 | $105 |
| Bayer | 5 | $103 |
| Abbott | 5 | $102 |
| Amgen | 5 | $101 |
| GSK | 5 | $85 |
| Pfizer | 4 | $72 |
| Lilly USA, LLC | 4 | $65 |
| Amarin Pharma, Inc. | 3 | $58 |
| Boston Scientific | 1 | $57 |
| Novartis | 3 | $53 |
| Sunovion Pharmaceuticals Inc. | 2 | $45 |
| AbbVie | 2 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Astellas Pharma US Inc | 1 | $26 |
| Edwards Lifesciences | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 2 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Biogen | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$1,504 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 21 | $8,044 |
| MyrbetriqMirabegron | 13 | $2,984 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $2,325 |
| Amiodarone Hcl | 13 | $1,189 |
| Tizanidine Hcl | 13 | $691 |
| Doxycycline Hyclate | 17 | $605 |
| Levothyroxine Sodium | 23 | $452 |
| Montelukast Sodium | 17 | $446 |
| Gabapentin | 18 | $383 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $354 |
| Lisinopril | 15 | $317 |
| FenofibrateFenofibrate Nanocrystallized | 13 | $288 |
| Atorvastatin Calcium | 23 | $283 |
| Pantoprazole Sodium | 14 | $282 |
| Amlodipine Besylate | 20 | $195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $26 | $2,98413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Inverness
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
- Jennifer PuleoTampa$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.